Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP reduced its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 31.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 129,062 shares of the biotechnology company's stock after selling 60,194 shares during the period. Dimensional Fund Advisors LP owned approximately 0.61% of Enanta Pharmaceuticals worth $1,674,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC purchased a new stake in shares of Enanta Pharmaceuticals during the 2nd quarter worth $35,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Enanta Pharmaceuticals in the 1st quarter worth about $118,000. Virtu Financial LLC purchased a new stake in shares of Enanta Pharmaceuticals in the 1st quarter worth about $191,000. Quest Partners LLC boosted its position in shares of Enanta Pharmaceuticals by 511.2% in the 2nd quarter. Quest Partners LLC now owns 11,588 shares of the biotechnology company's stock worth $150,000 after buying an additional 9,692 shares in the last quarter. Finally, American Century Companies Inc. boosted its position in shares of Enanta Pharmaceuticals by 35.4% in the 2nd quarter. American Century Companies Inc. now owns 27,892 shares of the biotechnology company's stock worth $362,000 after buying an additional 7,287 shares in the last quarter. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Scott T. Rottinghaus sold 5,375 shares of the company's stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $17.08, for a total transaction of $91,805.00. Following the completion of the transaction, the insider now owns 21,717 shares of the company's stock, valued at $370,926.36. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 13.64% of the company's stock.

Enanta Pharmaceuticals Price Performance

NASDAQ:ENTA traded up $0.41 on Friday, reaching $11.04. The stock had a trading volume of 142,265 shares, compared to its average volume of 207,562. The company has a market cap of $233.82 million, a price-to-earnings ratio of -1.77 and a beta of 0.58. The firm's fifty day moving average is $11.92 and its two-hundred day moving average is $13.22. Enanta Pharmaceuticals, Inc. has a 12-month low of $8.08 and a 12-month high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its earnings results on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.43) by $0.36. Enanta Pharmaceuticals had a negative net margin of 160.27% and a negative return on equity of 63.75%. The company had revenue of $17.97 million for the quarter, compared to analyst estimates of $17.44 million. During the same period in the prior year, the firm earned ($1.27) EPS. The firm's quarterly revenue was down 4.9% on a year-over-year basis. As a group, research analysts forecast that Enanta Pharmaceuticals, Inc. will post -5.3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Enanta Pharmaceuticals from $11.00 to $10.00 and set an "underweight" rating on the stock in a research report on Tuesday, August 6th. HC Wainwright reiterated a "buy" rating and issued a $27.00 price objective on shares of Enanta Pharmaceuticals in a research report on Thursday. Evercore ISI upgraded shares of Enanta Pharmaceuticals to a "strong-buy" rating in a research report on Tuesday, August 6th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $22.00 price objective on shares of Enanta Pharmaceuticals in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $20.00.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.